NAT1 and Crohn disease: Although comparing the dosage of mesalazine in our study with that used in Crohn’s disease treatment is challenging due to the drug’s rapid metabolism within the bowel, mesalazine undergoes swift metabolism by intestinal N-acetyltransferase 1 (NAT1) to an inactive form, N-acetyl-5ASA [34].